15 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has declined 31.3% per year over the past 5 years.
Operating margin has contracted, at -174.6% in the latest year.
Financial health
The company holds more cash ($1M) than total debt ($0).
Operating income covered interest expense -18.2× in the latest year.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
2025
$7M
-$45M
23.4%
-174.6%
—
$0
$1M
2024
$35M
-$168000
37.1%
-17.1%
-$4M
$2M
$3M
2024
—
-$43M
—
—
—
$36M
$106000
2023
$39M
-$23M
30.6%
-54.9%
$79000
$5M
$4M
2022
$55M
-$39M
27.9%
-71.0%
-$21M
$12M
$3M
2021
$46M
$3M
33.4%
-37.6%
-$12M
$10M
$22M
2020
$43M
-$59M
37.8%
-64.2%
-$8M
$33M
$4M
2019
$16M
-$184M
37.6%
-233.2%
-$21M
$37M
$2M
2018
$15M
-$6M
49.3%
-34.9%
-$7M
$6M
$4M
2018
—
-$3M
—
—
—
$1M
$199674
2017
—
-$2M
—
—
—
$553977
$1442
2016
—
-$933761
—
—
—
—
$10197
2015
—
-$49669
—
—
—
—
$0
2015
—
-$407289
—
—
—
—
$0
2014
—
-$388541
—
—
—
—
$0
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
Mar '26
$3M
-$6M
37.1%
-52.9%
—
$0
$21M
Dec '25
$3M
-$9M
37.5%
-135.0%
—
—
$13M
Sep '25
-$35M
-$15M
25.4%
-60.1%
—
$0
$1M
Jun '25
$11M
-$15M
29.9%
-152.2%
—
$31M
$912000
Mar '25
$7M
-$10M
33.3%
-15.2%
-$1M
—
$1M
Dec '24
$7M
-$4M
36.4%
-23.0%
$1M
$2M
$3M
Sep '24
$11M
-$32M
39.7%
-9.9%
—
$36M
$106000
Jun '24
$43M
-$3M
22.1%
-3.1%
—
—
$3M
Mar '24
$8M
-$3M
33.1%
-31.2%
-$1M
$5M
$4M
Dec '23
$6M
-$15M
9.3%
-223.1%
$983000
$5M
$4M
Sep '23
$13M
-$2M
33.8%
-19.9%
$343000
$5M
$4M
Jun '23
$11M
-$3M
34.1%
-24.5%
$236000
$3M
$4M
Mar '23
$9M
-$3M
35.1%
-35.2%
-$1M
$12M
$2M
Dec '22
$9M
-$24M
17.9%
-260.7%
-$3M
$12M
$3M
Sep '22
$12M
-$7M
35.1%
-54.0%
-$5M
$12M
$6M
Jun '22
$17M
-$4M
28.6%
-25.8%
-$5M
$12M
$11M
Mar '22
$17M
-$4M
27.7%
-23.3%
-$8M
$13M
$16M
Dec '21
$11M
-$5M
25.1%
-45.3%
-$4M
$10M
$22M
Sep '21
$13M
-$3M
33.6%
-30.1%
-$4M
$10M
$26M
Jun '21
$11M
$25M
35.5%
-29.1%
-$2M
$11M
$2M
Valuation over time
How the market has priced SRXH against its own fundamentals since 2025-04 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-sales ratio has fallen from 33.8× (Apr '25) to 8.4× (Jun '26).
Price / sales (P/S)
P/S
Frequently asked questions
Is SRXH growing its revenue and profit?
Over the past 5 years, SRx Health Solutions, Inc.'s revenue has declined 31.3% per year. These are computed facts, not advice.
How much debt does SRXH have?
As of FY2025, SRx Health Solutions, Inc. reported $0 of total debt against $1M of cash; operating income covered interest expense -18.2×.
What is SRXH's profit margin?
In FY2025, gross margin was 23.4%, operating margin -174.6%, and net margin -688.8%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.